Login to Your Account

Clinic Roundup

Monday, November 19, 2012
• CytoDyn Inc., of Portland, Ore., said it entered a clinical trial agreement with the Division of Infectious Diseases and HIV Medicine at Drexel University College of Medicine to conduct additional Phase II studies of PRO 140, a humanized monoclonal antibody targeting the CCR5 receptor for treating HIV infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription